

## Mouse Kdr Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP14955b

### **Specification**

## Mouse Kdr Antibody (C-term) Blocking Peptide - Product Information

**Primary Accession** 

P35918

# Mouse Kdr Antibody (C-term) Blocking Peptide - Additional Information

**Gene ID** 16542

#### **Other Names**

Vascular endothelial growth factor receptor 2, VEGFR-2, Fetal liver kinase 1, FLK-1, Kinase NYK, Protein-tyrosine kinase receptor flk-1, CD309, Kdr, Flk-1, Flk1

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

### **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

### Mouse Kdr Antibody (C-term) Blocking Peptide - Protein Information

Name Kdr {ECO:0000312|MGI:MGI:96683}

Synonyms Flk-1, Flk1

### **Function**

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as a negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and by preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5- trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production



of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

#### **Cellular Location**

Cell junction. Endoplasmic reticulum {ECO:0000250|UniProtKB:P35968}. Cell membrane {ECO:0000250|UniProtKB:P35968}. Note=Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (By similarity) Localized with RAP1A at cell-cell junctions {ECO:0000250|UniProtKB:P35968} [Isoform 2]: Secreted.

### **Tissue Location**

Expressed in endothelial cells (at protein level). Detected in embryonic endothelial cells, as well as hematopoietic stem and progenitor cells. Detected in vascular endothelium. Expressed at high levels in adult heart, lung, kidney, brain and skeletal muscle, but is also expressed at lower levels in most other adult tissues

## Mouse Kdr Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### Blocking Peptides

Mouse Kdr Antibody (C-term) Blocking Peptide - Images

Mouse Kdr Antibody (C-term) Blocking Peptide - Background

Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability.